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1384 LETTERS TO THE EDITORselected forms of primary immunodeficiency with autoimmune
features.
Our patients illustrate that different types of mutations in a
given gene might be associated with vastly different clinical
phenotypes.10 Further investigation of the mutation identified in
this report might help to elucidate the function of this gene in
relation to this CVID-like but more complex immunodeficiency.
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Long-term remission after allogeneic hema-
topoietic stem cell transplantation in LPS-
responsive beige-like anchor (LRBA) deficiency
To the Editor:
LPS-responsive vesicle trafficking, beach and anchor
containing protein (LRBA) deficiency has been identified as a
primary immunodeficiency (PID) characterized by recurrent
infections associated with autoimmunity, such as inflammatory
bowel disease and autoimmune cytopenias (see Fig E1 in this ar-
ticle’s Online Repository at www.jacionline.org).1-3 Awide range
of immunosuppressive treatment measures have only induced
temporary relief in affected subjects. Although allogeneic
hematopoietic stem cell transplantation (HSCT) is the current
treatment for many forms of PIDs, HSCT is less established in
patients with autoimmune disease4,5 and has not yet been reported
in LRBA-deficient patients.
We studied a consanguineous family of Kurdish origin with a
systemic autoimmune disorder. Patient 1’s symptoms started at 2
years of age with immune thrombocytopenia (ITP; Fig 1, A).
Serum immunoglobulin concentrations were slightly increased,
and the cellular immunophenotype was normal (Table I and see
Table E1 in this article’s Online Repository at www.jacionline.
org). A lymph node biopsy performed because of generalized
lymphoproliferative disease (LPD) revealed a follicular
lymphatic hyperplasia with abundant (about 20% to 30%)
CD31 and CD42 and CD82 double-negative T lymphocytes
(DNT cells; Fig 1, C), suggesting an immune dysregulation,
lymphocytematuration, or apoptosis defect compatiblewith auto-
immune lymphoproliferative syndrome (ALPS).6,7 HSCT was
performed with the clinically healthy HLA-identical mother as
the donor (see the additional text in this article’s Online Reposi-
tory at www.jacionline.org), leading to complete remission with
persisting full donor chimerism and without signs of acute or
chronic graft-versus-host disease (GvHD). Four years after
HSCT, ITP relapsed but responded well to high-dose intravenous
immunoglobulin (IVIG) treatment. When romiplostim was
started, platelet counts normalized, and administration of
romiplostim (5 mg/kg, every 4 to 6 weeks) without further need
for immunosuppression or IVIG has led to sustained but
treatment-dependent remission.8
Patient 2, the now11-year-oldyounger sister of patient 1, became
symptomatic at 5 years of age (fulminant autoimmune hemolytic
anemia; Fig 1, B). Immunosuppression was started immediately
(corticosteroids, mycophenolate mofetil, and vincristine), leading
to a sustained remission (Fig 1, B). Rituximab was administered
AB
FIG 1. Clinical course of a familial autoimmunity syndrome caused by LRBA deficiency, immuno-
histochemical analysis of lymph node specimens (patient 1), and histologic assessment of gastrointestinal
biopsy specimens (patient 2). A, Clinical course of a now 19-year-old girl, patient 1, including treatment and
HSCT at the age of 10 years. B, Symptoms and treatment outline of patient 2. C, C.1, Triple immuno-
histochemical staining of T-cell markers showing increased double-negative T-cell numbers marked only
with an antibody against CD3 (light blue/gray, dashed arrow), which is reminiscent of CD95 deficiency;
CD41 (brown, solid arrow) and CD81 (purple, open arrow) T cells are also shown. C.2, Duodenal biopsy
specimens showing focal villous flattening and intraepithelial lymphocytosis. C.3, Colon mucosa with
moderate crypt distortion and sparse apoptotic bodies. C.4, Signs of vasculitis indicated by abundant
neutrophilic granulocytes within and migrating through the lamina propria capillaries of the colon mucosa.
Plasma cells were absent in all sections. AdV, Adenovirus; AIHA, autoimmune hemolytic anemia; ATG-F,
anti-thymocyte globulin-Fresenius (Fresenius Medical Care, Vienna, Austria); AZT, azidothymidine; cITP,
chronic immune thrombocytopenia; CsA, cyclosporin A; ENT, ear, nose, and throat; IVIG, intravenous
immunoglobulin subsitution; LPD, lymphoproliferative disease; MFD-BMT, matched family donor bone
marrow transplantation; MMF, mycophenolate mofetil; PEG tube, percutaneous enterogastral tube; TPN,
total parenteral nutrition; SCIG, subcutaneous immunoglobulin subsitution; UTI, urinary tract infection.
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cially given the severe course of her sister. Before treatment, immu-
noglobulin concentrations were mildly reduced (4.61 g/L IgG,
normal IgA level, and 0.18 g/L IgM; Table I), direct and indirect
Coombs test and platelet antibody results were positive, and DNT
cell numbers were increased (3.4% of CD31 cells), with an other-
wise normal cellular immune phenotype (Table I and see TableE1),
suggesting a familialALPS-like disorder.Chronic enteropathywith
increased calprotectin levels, borderline reduced elastase
levels, and chronic norovirus positivity in stool were
diagnosed. Gastroduodenoscopy specimens of patient 2 revealed
inflammatory bowel disease, absence of plasma cells, and
vasculitis (Fig 1,C; and see Fig E2,D-I, in this article’s Online Re-
pository at www.jacionline.org). She is being treated with
budesonide and IVIG (1 g/kg body weight twice per month; trough
level, 8-10 g/L) and requires parenteral nutrition (12-14 hours per
night).
The fact that 2 patients born to consanguineous parents
presented with a similar clinical phenotype prompted us to
screen for an underlying (mono-) genetic defect. Homozygous
intervals were mapped by applying the GeneChip Human-
Mapping-250K-Nsp-Assay (Affymetrix, Santa Clara, Calif).
Homozygous stretches were identified and overlaid with
HomozygosityMapper.9 Both patients had identical homozy-
gous intervals on chromosomes 2, 3, 4, 9, 11, and 15 (Fig 2,
A). Exome sequencing and subsequent computational analysis
of patient 1 revealed 23,582 exonic variants, of which 30
were rare missense, nonsense, or splice-site variants located in-
side the shared homozygous regions of the 2 siblings (see Table
E2 in this article’s Online Repository at www.jacionline.org).
Among the final variant list, one frameshift deletion was
identified, resulting in a premature stop codon. This mutation
(NM_001199282:c.7162delA; p.T2388Pfs*7) is located inside
the gene encoding LRBA. Sanger sequencing confirmed the
presence and segregation of the variant, suggesting anautosomal recessive defect with full penetrance (Fig 2, B).
Expression of the corresponding protein product was near ab-
sent (Fig 2, C).
Taken together, we describe a clinical, immunologic, and
genetic analysis of 2 patients presenting with multiorgan
autoimmunity and severe infections caused by a novel mutation
in LRBA, the clinical spectrum of which both recapitulates and
extends the previously described phenotypes (see additional
text in this article’s Online Repository).1-3 The fact that patient
1 had a profound immunodeficiency with life-threatening
infections and refractory autoimmunity justified the approach of
allogeneic matched family donor HSCT according to
international guidelines.4,5 In our case allogeneic HSCT resulted
in long-lasting partial remission in the patient with LRBA
deficiency. The observation that mild autoimmune symptoms
(ITP and vitiligo) have recurred in patient 1 years after HSCT
despite full donor chimerism might be due to reduced LRBA
expression compared with a healthy donor (in the same range
as the heterozygous stem cell donor, who has detectable
autoantibodies without clinical symptoms; see Fig 2, C, and
additional text in this article’s Online Repository), thus
representing residual disease activity or late, limited chronic
GvHD. These data show that HSCT might be a treatment option
for patients with LRBA deficiency.
We thank the patients and their family for their trust, cooperation,
and consent to perform genetic analyses. We also thank the pediatric
hematology-oncology staff, including mobile pediatric nurses and documen-
tary assistants. During early diagnostic steps, Professors Debatin (Ulm),
Belohradsky (Munich), and Seger (Zurich) provided helpful expert advice.We
thank Professor Ehl (Freiburg) for fruitful discussions on ALPS-U and
differential diagnoses.
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TABLE I. Laboratory parameters of 2 patients with LRBA deficiency
Patient 1 Patient 2
Before HSCT After HSCT Before rituximab After rituximab
Humoral immune system 99.98% donor chimerismk{{*** (IVIG substituted)
IgG (g/L) 16.7 (6.5-14.1)* 11.3 (7-16)*** 4.61 (5.5-12)** NA
IgG1 (g/L) 9.1 (3.5-9.1)* 7.85 (4.05-10.11)*** NA NA
IgG2 (g/L) 3.06 (0.85-3.30)* 3.69 (1.69-7.86)*** NA NA
IgG3 (g/L) 1.83 (0.2-1.04)* 0.879 (0.11-0.85)*** NA NA
IgG4 (g/L) 0.01 (0.03-1.58)* 0.481 (0.03-2.01)*** NA NA
IgA (g/L) 1.24 (0.83-2.17)* 2.61 (0.7-4.0)*** 0.28 (0.21-2.92)** <0.08 (0.31-3.06)kk
IgM (g/L) 1.43 (0.55-2.10)* 1.64 (0.4-2.3)*** 0.18 (0.37-1.41)** 0.02 (0.47-1.0)kk
IgE (kU/L) 24.7* (<110) 44 (0-100)*** <19 <19
Autoimmunity (selected autoantibodies)
Coombs test, direct 1:64* Negative*** Positive, 1:16-64{#** Negative
Coombs test, indirect Positive* Negative*** Positive{# Negative
Anti-platelet antibodies Positive Positivek j negative*** Positive# Negative
ANA Negative Negative Negative Negative
dsDNA antibody Negative Negative Negative Negative
Cardiolipin IgG antibody (U/mL) 14* (0-10) 33§ j 2.3*** (0-10) Negative Negative
SMA (U/mL) 50* (negative) 200§ j negative*** (negative) Negative Negative
AMA Negative* Positive,§ *** (negative) Negative Positive j negative
M2 antibody## (U/mL) Negative* 45.6k j 88.0*** (0-5) Negative Negative
Cellular immune system
CD31 T cells/mL 1,930 (700-4,200) 736*** (700-2,100) 2,799# (1,400-8,000) 1325§§ (700-4,200)
CD31CD41 cells/mL 1,511 (300-2,000) 324*** (300-1,400) 2,010# (900-5,500) 931§§ (300-2,000)
CD31CD81 cells/mL 296 (300-1,800) 367*** (200-900) 601# (400-2,300) 325§§ (300-1,800)
CD45RA1CD41CD31 cells
(% of CD31CD41 cells)
64 (>15%) 8.5{{ j 6*** (>10%) 57# (>15) 26§§ (>10%)
abTCR1CD31 cells/mL ND 638k 2,578# 1,097§§
gdTCR1CD31 cells/mL ND 10k 137# 39§§
abTCRCD31CD42CD82
(DNT cells [% of CD31 cells])
0.95% to 3%* (<2) 0.03%*** (<2) 0.4%# (<2) 3.24%§§ (<2)
CD32CD561 NK cells/mL 108 (90-900) 140*** (200-300) 291# (100-1,400) 81§§ (90-900)
iNKT cells Va24Vb11
(% of CD31 cells)
ND 0.1%{{ (>0.01) ND 0.02%kk (>0.01)
CD191 B cells/mL 335-118* (200-1,600) 213{{ (100-500) 413# (200-2,100) 32 (200-1,600)
CD191IgD1CD271 cells
(% of CD191 cells)
ND* 0.38k j 30{{ (>2) ND# 0.02 (>2)
CD191IgD2CD271 cells
(% of CD191 cells)
ND* 0.08k j 31{{ (>2) ND# 0.00 (>2)
Lymphocyte stimulation in vitro
detected based on tritiated
thymidine incorporation (trigger
and antigens in parentheses)
Normal (PHA, SEB, CD3,
PMA/ionomycin)
ND ND Normal unstimulated:
1,716 cpm (1,650-
7,162 cpm)
PHA: 16,513 cpm
(14,218-39,235 cpm)
Concanavalin A: 11,384
cpm (4,928-29,519 cpm)
CD3/CD28: 17,746 cpm
(12,181-31,490 cpm)
Footnotes indicate time point of analysis. Pathologic results are shown in boldface (normal ranges are shown in parentheses).
AMA, Anti-mitochondrial antibodies; ANA, antinuclear antibody; dsDNA, double-stranded DNA; iNKT, invariant natural killer T; NA, not applicable under IVIG substitution and
not done before IVIG; ND, not done; NK, natural killer; PHA, phytohemagglutinine; PMA, phorbol 12-myristate 13-acetate; SCT, stem cell transplantation; SEB, staphylococcal
enterotoxin B; SMA, smooth muscle autoantibodies; TCR, T-cell receptor.
*At 6 years of age.
At 8 years.
§At 10 years.
kAt 14 years (4 years after stem cell transplantation).
{At 17 months.
#At 2 years.
**At 5.5 years before immunosuppression/rituximab.
At 7.5 years of age.
At 9 years of age.
§§At 10 years of age.
kkAt 11 years of age.
{{At 19 years of age (9 years after HSCT).
##Subfraction of antimitochondrial antibodies directed against the M2 fraction of liver cell mitochondrial antigens located on inner mitochondrial membranes (comprising proteins
of the 2-oxo-acid dehydrogenase complex).
***At 19.5 years of age (10 years after stem cell transplantation).
See the Methods section in this article’s Online Repository.
On repeated occasions.
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Immune factors in breast milk related to infant
milk allergy are independent of maternal atopy
To the Editor:
The first few months of life represent a window of opportunity
for neonatal oral tolerance induction. During this critical time,
breast milk is a rich source of immunomodulatory factors,
including TGF-b, which has been shown to influence the
maturation of the mucosal immune system of the neonates.1
Reports on breast milk cytokines, chemokines, and growth
factors in cow’s milk allergy (CMA), including both IgE- andbetweenmothers with a CMA infant and those with
t, shown after logarithmic transformation). E,Multi-
e U-statistics). On the box plots’ horizontal line, me-
percentile; round symbol, geometric mean.
Within the last 10 to 15 years, the paradigm of PIDs defined as
inborn errors of immune cells causing a dangerous predisposition
toward infections has been extended to include immune dysre-
gulation syndromes and autoimmunity. This development was
based on the identification of defects in regulatory cell subsets,
such as forkhead box P3–positive and other regulatory T
cellsE1,E2; perturbed T- and B-cell maturation and tolerance
checkpoint defectsE3,E4; and dendritic cell–and phagocyte-
mediated immune regulation.E5,E6 This is reflected by the modifi-
cation of diagnostic criteria and the most recent classification of
PIDs.E7-E10 LRBA protein deficiencywas identified as a novel hu-
man disease gene causing PIDs with associated autoimmunity,
including enteropathy and other autoimmune symptoms.E11-E13
However, the functional role of LRBA has remained largely
elusive.
LRBA was initially identified as an LPS-inducible gene in B
cells and macrophagesE14 and is comprised of a ‘‘beige and Che-
diak-Higashi’’ (BEACH) domain, a pleckstrin homology and a
WD40 repeat domain, which collectively are likely required for
protein-protein and DNA-protein interactions.E14,E15 It has been
shown that the BEACH-WD40 domains of LRBA associate
with lysosomes, the endoplasmic reticulum, the Golgi
apparatus, the plasma membrane, and endocytotic vesicles,
corroborating a role for LRBA in polarized vesicle transport.E14
LRBA-deficient B cells show defects in autophagy and
apoptosis.E11,E16
Some LRBA-deficient patients were reported to have early-
onset primary hypogammaglobulinemia and reduced numbers of
class-switched memory B cells,E11 suggesting a diagnosis of
hyper-IgM syndrome or common variable immunodeficien-
cy.E17-E20 Other patients initially presented with autoimmune
cytopenia or inflammatory bowel disease but normal immuno-
globulin concentrations.E12,E13 Overall, the hitherto 11 published
patients present with a broad spectrum of symptoms, as summa-
rized in Fig E1. Allogeneic HSCTas a treatment option in patients
with refractory autoimmune disease is discussed controversially
as either being considered a useful replacement of the immune
system with the additional option of a beneficial concomitant
‘‘graft versus autoimmunity’’ effect or seen as too dangerous
because of higher morbidity and mortality with uncertain curative
potential.E21-E25
METHODS
Flow cytometry
In addition to routine chemistry and clinical immunology laboratory
analyses, special immunologic analyses included flow cytometry (fluores-
cence-activated cell sorting) performed on a Cytomics FC500 flow cytometer
(Beckman Coulter, Brea, Calif) with a panel of mAbs from Beckman Coulter
(Vienna, Austria), Becton Dickinson (Vienna, Austria), Dako (Glostrup,
Denmark), Miltenyi Biotech (Vienna, Austria, and Bergisch Gladbach,
Germany), as described previously.E26
Functional and apoptosis assays
To test lymphocyte proliferation in vitro, mononuclear cells (1e5) from pe-
ripheral blood of healthy donors and patients were incubated with PHA (12.5
mg/mL; Sigma Chemicals, St Louis, Mo), soluble CD3 mAb (2 mg/mL;
OKT3, Ortho, Raritan, NY), phorbol myristate (1027 mmol/L, Sigma Chem-
icals), or medium in round-bottom 96-well culture plates for 72 hours, after
which cells were pulsed with methyl-tritiated thymidine (1 mCi per well)
for 18 hours and processed as described previously.E27 Apoptosis assays
were performed, as described elsewhere.E28 Phagocytosis and oxidative burst
were detected with dihydrorhodamine-123.
Immunohistochemical analysis and in situ
hybridization
Sections of formalin-fixed, paraffin-embedded tissue specimens were stained
with mouse anti-human CD3 (clone F7.2.38; dilution 1:50; Dako, Glostrup,
Denmark), mouse anti-human CD8 (clone C8/144B; dilution 1:30; Dako), and
mouse anti-human CD4 (clone 4B12; dilution 1:20; Labvision, Fremont, Calif)
mAbs, according to the supplier’s specifications. In situ hybridization of EBV
RNA was done with the INFORM EBER probe (Ventana-Roche, Mannheim,
Germany), according to the supplier’s specifications.
Genetic analyses
Both affected subjects were genotyped on the Affymetrix GeneChip
Human Mapping 250K Nsp Array at the Center for Medical Research at the
Medical University of Graz. Autozygosity mapping was performed with
dCHIP (http://biosun1.harvard.edu/complab/dchip).E29 Exome sequencing
was performed, applying the Nextera Exome Enrichment Kit (Illumina, San
Diego, Calif), according to the manufacturer’s recommendations. In brief,
50 ng of genomic DNAwere tagmented (tagged and fragmented) with Nextera
transposase. This process simultaneously added adapter sequences, which
were used as primer-binding sites for a limited-cycle PCR. After purification
steps, the 12-plexed library was mixed with capture probes for enriching
exonic regions and PCR amplified. Cluster generation was performed with
the Illumina cBot Cluster Generation System according to the TruSeq PE
Cluster Kit v3 (cBot-HS Reagent Preparation Guide, Illumina). Sequencing
was performed on a HiSeq2000 (Illumina) applying the TruSeq SBS Kit v3-
HS (200-cycles). Reads were demultiplexed with Casava. Alignment to the
human genome hg-19 was done, applying the Burrows-Wheeler aligner.
The Genome Analysis Toolkit was used to call single nucleotide and inser-
tion/deletion variants.
LRBA expression by means of fluorescence-
activated cell sorting analysis
PBMCs were isolated from venous blood of a healthy donor, the
heterozygous mother, and both patients with Lymphoprep (Axes-Shield
Kabi Norge As, Oslo, Norway). After stimulation with 10 ng/mL PHA
(L1668; Sigma, St Louis, Mo) for 72 hours at 378C in a 5% CO2 atmosphere,
intracellular expression of LRBA in unstimulated and stimulated PBMCs
was measured by using flow cytometry. Briefly, cells were first permeabilized
and fixated with BD Cytofix/Cytoperm solution (BD Biosciences,
Heidelberg, Germany) and then stained with rabbit polyclonal anti-LRBA
antibody (HPA019597; Sigma-Aldrich, Munich, Germany) for 30 minutes
at 48C. Subsequently, a phycoerythrin-conjugated secondary antibody against
the LRBA antibody (PE[ab9]2 Donkey anti-rabbit IgG, reference 558416, BD
Biosciences) was added and incubated for 30 minutes. Cells were then
washed and analyzed on a FACSCanto II. Data analysis was performed
with FlowJo software (version 7.6.5; TreeStar, Ashland, Ore).
RESULTS
Further information on the clinical course and
immune phenotype of 2 sisters with LRBA
deficiency
Patient 1. Patient 1, a now 19-year-old girl of consanguineous
Turkish parents of Kurdish origin presented with ITP at the age of
2 years, which was responsive initially to immunoglobulin
treatment (Fig 1, A, and see Fig E1, B). The girl soon started to
experience recurrent ear, nose, and throat and airway infections
that required repeated courses of oral antibiotics. Starting at
age 4 years, her weight gain decelerated, and generalized
lymphadenopathy was reported (incipient LPD; Fig 1, A). The
patient presented with relapsing pneumonia and pancytopenia at
the age of 6 years. Additionally, she became dystrophic. At age
6 years, her weight was at the third percentile (16 kg), and her
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length was at the 10th percentile (110 cm). Hepatosplenomegaly,
LPD, fatty stools, and diarrhea were noticed. Elastase in stool was
22 mgE1/mg (normal, 200-2500), indicating exocrine pancreas
insufficiency. After repeated courses of IVIG treatment, we tested
the vaccine response during an IVIG-free interval and found a
good response to polio, Haemophilus species, and tetanus. Cyto-
megalovirus was detected in the urine, but anti-cytomegalovirus
IgG levels were negative. Levels of gliadin-directed IgA and
IgG and various autoantibodies, including phospholipid and
smooth muscle antibodies, and Coombs test results were positive
(Table I and see Table E1), indicating multiorgan autoimmunity.
The pancytopenia responded well to reinitiation of IVIG therapy;
chronic diarrhea was observed, and inflammatory disease was
diagnosed clinically but never verified by means of gut biopsy.
The clinical presentation suggested ALPS, and corresponding
immunologic and genetic analyses were performed. Repeated an-
alyses of CD31CD42CD82TCRa/b1 (DNT) cells identified be-
tween less than 1% and 3% of CD31 T cells at 6 to 8 years of age,
and results of other cellular analyses, including apoptosis assays
and mitogen stimulation in vitro, performed at that time were
normal (Table I and see Table E1). DNA sequence analysis of
CD95, CD95L, caspase 8, caspase 10, SAP, and XIAP showed
no pathogenic mutation.
The conditioning regimen consisted of 5 3 30 mg/m2
fludarabine, 33 20 mg/kg ATG-F, and 23 70 mg/m2 melphalan
(Fig 1, A). The bone marrow graft contained 5.53 106/kg CD341
stem cells and 4.2 3 107/kg CD31 T cells. Standard GvHD
prophylaxis, consisting of cyclosporine A intermittently
supplemented with corticosteroids and mycophenolate mofetil
(MMF; Fig 1, A), was administered. The post-HSCT period was
complicated by adenovirus viremia and hepatopathy, as well as
suspected graft failure caused by pancytopenia (despite complete
donor chimerism) potentially linked to viral reactivation and
immunodysregulation around day 160, prompting a stem cell
boost with growth factor support. This ultimately led to stable
engraftment with 100% donor chimerism until today. A liver
biopsy on day 1123 after HSCT showed no signs of GvHD but
was compatible with viral (HHV6 or adenovirus induced) or toxic
damage. There were no other signs of GvHD. Antiviral therapy
was intensified, and the regular post-HSCT immunosuppression
(cyclosporin A, corticosteroids, and short-term MMF) was
tapered. Liver parameters remained increased (between 3 and
10 times the upper limit of normal, predominantly alanine
aminotransferase) and smooth muscle and anti-mitochondrial
antibodies (especially of the M2 subfraction), which are often
associated with primary biliary cirrhosis (PBC), were detectable
(Table I and see Table E1). Four years after HSCT, treatment
for suspected alloimmune/autoimmune hepatitis could be
terminated based on normalized liver parameters, but the
recurrence of ITP (platelet counts: 11,000-16,000/mL; constantly
>100,000/mL since engraftment) led to short and unsatisfying at-
tempts at intensified systemic immunosuppression withMMFand
rapamycin. The direct Coombs test was not done at the reoccur-
rence of ITP because RBC and hemoglobin levels were normal;
however, a recent evaluation showed negative direct Coombs
test results and negative anti-platelet autoantibody levels (Table
I). Furthermore, patient 1 had no detectable viral load at various
occasions within the last 4 years.
Notably, recent laboratory investigations of the maternal
donor performed 9 years after the HSCT of her daughter showed
an identical pattern of anti-mitochondrial autoantibodies,
suggesting a subclinical familial predisposition to PBC-
associated autoantibodies.
The mother had a negative direct Coombs test result and
negative antinuclear and borderline positive platelet antibody
levels but not other autoantibodies or clinical evidence of
autoimmunity like her daughters, such as vitiligo, immune
cytopenia, or other diseases. She is under yearly observation at
the hepatology department and has normal alkaline phospha-
tase and gamma-glutamyl transferase levels, and results of
both liver function tests and liver ultrasound are unremark-
able. Other heterozygous family members (the father and
brother of patients 1 and 2) had negative test results for
autoantibodies.
In patient 1 a second and a third liver biopsy were performed on
days 200 and 330 after HSCT, showing progressive fibrosis with
massive portal lymphocytic and histiocytic infiltration sparing
bile ducts, as well as Kupffer cell and parenchymal (hepatocyte)
siderosis compatible with chronic autoimmune hepatitis or viral/
toxic damage but no signs typical for GvHD or biliary cirrhosis.
No viral nucleic acid was detectable in liver parenchyma or
blood on that occasion or later. Immunosuppression against
autoimmune hepatitis, namely corticosteroids and azathioprine,
was started (Fig 1, A) and slowly ameliorated hepatopathy. Only
last year, the patient started to experience vitiligo, and topical
steroid treatment was initiated, leading to stabilization of the
disease. It is unclear whether this condition is an alloimmune
response (ie, late chronic GvHD) or caused by the underlying
autoimmune disease.
Patient 2. Patient 2 had been evaluated earlier during
infancy as a potential stem cell donor, when RBC-directed and
platelet antibodies were detected but B, T, and DNT cell
numbers and additional cellular immunologic analyses were
normal. Before treatment, her weight and body length were
between the 90th and 97th percentiles. Notably, the patient’s
immune system never recovered from anti-CD20 treatment,
with ongoing B-cell deficiency, complete lack of class-
switched memory B cells, and profound hypogammaglobulin-
emia resembling common variable immunodeficiency (Table I)
that required initiation of immunoglobulin substitution. Soon
after the first clinical manifestation, patient 2 started to experi-
ence recurring urinary tract infections without anatomic pre-
disposition, and recurrent virus-induced diarrhea began
(norovirus, adenovirus, or both were detectable on various oc-
casions; Fig 1, B).
Stomach biopsy specimens showed chronic gastritis in the
gastric corpus, with apoptotic bodies within and apoptotic debris
underneath the epithelium and focally enhanced chronic active
gastritis in the antrum (Fig 2, B-D, and see Fig E2, D-I). Colonic
biopsy specimens showed epithelial cell damage indicated by
apoptotic bodies within and underneath the epithelium, as well
as chronic mucosal damage indicated by moderate crypt
distortion; sparse apoptotic bodies could be seen in the epithelium
of the crypts; and abundant neutrophilic granulocytes within and
migrating through capillaries within the lamina propria indicative
of vasculitis were evident, although plasma cells were absent
(Fig 2, B-D, and see Fig E2, D-I). EBV RNA was detected in
several epithelial nuclei in the stomach, as well as duodenal
biopsy specimens (see Fig E2, H). Malabsorption and growth
arrest were observed, which did not improved with a gluten-
free diet over 18 months or tube feeding with formula nutrition.
After total parenteral nutrition (TPN) was commenced at 10 years
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of age, when body length and weight were at the third percentile,
she restarted to thrive in parallel to the third percentile. Addition-
ally, mild hepatopathy with increased transaminase levels but
without signs of cholestasis started at 7.5 years of age and has per-
sisted to date. Anti-mitochondrial antibodies but neither smooth
muscle nor M2 antibodies were detectable; no liver biopsy has
been performed. Albumin concentrations and levels of the bile
duct enzymes alkaline phosphatase and gamma-glutamyl trans-
ferase have been normal. Various attempts at systemic or topical
immunosuppression with corticosteroids or rapamycin to treat her
enteropathy were of limited and/or short-term success. One
episode of bilateral gonarthritis at the age of 9.5 years was noted,
which responded to nonsteroidal anti-inflammatory drugs.
DISCUSSION
Here we report 2 patients harboring a novel mutation of LRBA
(NM_001199282:c.7162delA; p.T2388Pfs*7). The patients
presented with several severe symptoms, many of which have
been described previously, such as cytopenias and lymphoproli-
ferative syndrome (Fig 1, A and B, and see Fig E1),E11-E13 and
some novel additional findings, such as exocrine pancreas
dysfunction and intestinal vasculitis. The occurrence of primary
hypogammaglobulinemia is controversial in patients with
LRBA deficiency because this has been described only in some
subjects.E11 Other patients, including the 2 patients treated at
our institution, presented with normal immunoglobulin levels
and antibody production before initiation of immunosuppressive
treatment.E12,E13 Thus in summary, the phenotype of LRBA
deficiency can include chronic diarrhea/inflammatory bowel
disease; immune cytopenia; recurrent bacterial infections of the
airways, ear/nose/throat, and other organs; and various
other autoimmune/immune dysregulatory features, including
arthritis, glomerulonephritis, gastritis, diverse dermatologic
manifestations, lymphoproliferative disease, central nervous
system granuloma (Fig 1, A and B, and see Fig E1), and
hypogammaglobulinemia.
Currently described mutations in LRBA include large dele-
tions, frameshift mutations that lead to a premature stop
codon, and 1 C-terminal missense mutation.E11-E13 All of these
mutations lead to an absence of protein expression. Our novel
mutation was detected by using exome sequencing and is a sin-
gle base pair deletion at position c.7162, causing a frameshift
in exon 47 (p.T2388fs*7) and leading to a translational stop
before the alpha-H helix of the BEACH domain in the C-ter-
minal region of the protein,E15 likely inducing nonsense-
mediated decay. This domain is involved in intramolecular,
protein-protein, and protein-DNA interactions. Comparing
the clinical symptoms of immunodeficiency and autoimmunity
of our patients with those of the previously described patients
with respect to their mutations and considering that in all pa-
tients LRBA protein is completely missing, it is not possible to
draw any conclusion on a potential genotype-phenotype
correlation.
Although certain refractory courses of systemic sclerosis,
multiple sclerosis, systemic lupus, Crohn disease, and other
autoimmune diseases are becoming a standard indication for
autologous stem cell transplantation,E30 the indications for
allogeneic HSCT in patients with autoimmune diseases remain
controversial, given the risk of histoincompatibility reactions,
such as GvHD, and the increased incidence of life-threatening
infections in the allogeneic setting compared with autologous
stem cell reinfusion. This debate is reflected by a number of
reviews and meta-analyses on various autoimmune disease
subgroups.E21-E25 In general, the agreement on HSCT as a
possible therapy is higher in autoimmune diseases involving
cytopenias than in those involving a single organ. With the
exception of a certain number of cotransplanted peripheral
memory and effector T cells, replacement of a deficient immune
system through allogeneic HSCT results in a reset of tolerance-
inducing mechanisms with newly arising naive T and B cells
that undergo central and peripheral tolerance checkpoint editing.
This implies that any autoimmune pathomechanism that arises
from defective immune or blood-derived cells, including
antigen-presenting cells, should be correctable.
The high degree of consanguinity within this family, as well as
the HLA identity of the mother with both daughters, estimated a
smaller amount of antigen disparity than in an unrelated donor
allogeneic setting. To what extent the graft and sustained
complete donor chimerism conferred a lasting cure for patient
1’s PID remains to be seen; however, 9 years of follow-up after
HSCT revealed a good partial remission with moderate cITP,
vitiligo, and subclinical presence of M2 autoantibodies without
any reduction in patient-reported quality of life. The fact that the
LRBA-heterozygous maternal donor also has anti-mitochondrial
antibodies without clinical symptoms of PBC like her daughters
might have 2 implications.
First, perhaps the heterozygosity of the LRBA frameshift
mutation in the mother associated with a reduction in LRBA
protein concentration is pathomechanistically relevant. This has
not been documented before because heterozygous relatives
were silent carriers in previously described families,E11 although
it is unclear whether all clinically healthy carriers were tested for
the presence of any autoantibodies. In that case the allogeneic
HSCT in patient 1 might resemble in part an autologous HSCT
with a reset of the immune system and an ameliorated but not fully
corrected LRBA deficiency.
Second, another familial predisposition toward PBC-
associated autoantibodies than the LRBA deficiency of patients
1 and 2 exists that also affects the mother. PBC is more frequent in
female than male subjects [9:1], and a familial predisposition is
indicated by the highly increased risk in monozygotic twinsE31
and association with HLA-DRB1*08, HLA-DQB1, and other
loci, including IL12A, IL12RB2, STAT4, and CTLA4,
respectively.E32,E33 In the presented family we found 3 heterozy-
gous single nucleotide polymorphisms in 3 genes (rs3748816 in
MMEL1, rs907092 in IKZF3, and rs2305480 in GSDMB), which
were recently revealed to be associated with an increased risk of
PBC in genome-wide association studies,E32,E33 suggesting the
presence of an additional polygenetic predisposition toward M2
autoantibodies and potentially PBC in this pedigree apart from
LRBA deficiency.
The younger sibling has been considered a candidate for stem
cell transplantation since the first presentation after the
experience of patient 1, but 3 factors have argued against it.
First, it was suspected that the patient’s bowel inflammation
represented an unpredictable risk and might not benefit from
HSCT given the chronic norovirus infection and near-total
malabsorption. Second, an LRBAwild-type HLA-matched donor
would be preferable instead of the HLA-identical mother, who
was a heterozygous carrier of the LRBA mutation, but such a
donor was not available. Third, combined HSCT and bowel
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transplantation with potentially only partial reconstitution of
LRBA expression from the HLA-identical but LRBA-
heterozygous mother appeared too experimental, given that under
TPN, the girl attends school and showed near-normal physical
development for the last 2 years. Nevertheless, any deterioration
of her disease state would warrant a re-evaluation of the potential
risks and benefits of HSCT.
Today, facing a total of only 13 published patients, including
the 2 LRBA-deficient patients described here, it is unclear
whether HSCT should be recommended generally on diagnosis.
A high variation of the clinical severity is known from other PIDs
with immunodysregulation, such as combined immuno-
deficiencies, immune dysregulation–polyendocrinopathy–enter-
opathy–X-linked syndrome, and CD27 deficiency.E34-E38
Although it appears probable that our patient 2 might have
benefited from early HSCTand many of the previously described
other clinical courses were severe, deriving a more comprehen-
sive map of genotype-phenotype correlation and the natural
course of LRBA deficiency requires longer follow-up and
detection of more patients with different genotypes.
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FIG E1. Spectrum and timely appearance of clinical symptoms of 11 previously published patients with
LRBA deficiency. The time point (patient age) of the first documentation and, if possible, the end of a certain
clinical condition of 11 children and young adults with LRBA deficiency are grouped according to the organ
manifestation in ‘‘hematology,’’ ‘‘infections,’’ ‘‘enteropathy,’’ and ‘‘other’’ (from bottom to top), according to
recent publications by Lopez-Herrera et al,3 Alangari et al,1 and Burns et al.2 Only the primary immune and
autoimmune diseases, but not secondary symptoms, such as finger clubbing, or cor pulmonale, are shown.
AIHA, Autoimmune hemolytic anemia; AI-pancytopenia, autoimmune pancytopenia; CNS, central nervous
system; ENT, ear, nose, and throat; infx, infections; ITP, immune thrombocytopenia; LIP, lymphocytic inter-
stitial pneumonitis; LPD, lymphoproliferative disease.
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FIG E2. Histologic assessment of lymph node and gastrointestinal biopsy specimens. A-C, Consecutive
lymph node sections showing an increased CD4/CD8 T-cell ratio. D, Duodenal biopsy specimens showing
focal villous flattening. E, EBV RNA–positive enterocyte nuclei in duodenal biopsy specimens. F,Moderate
chronic gastritis with apoptotic cell debris underneath the surface epithelium in the gastric corpus.
G, Focally enhanced chronic active gastritis in the gastric antrum. H, EBV RNA–positive antral epithelial
cells. I,Apoptotic cell debris beneath the surface epithelium in the colonicmucosa. Plasma cells were absent
in all sections.
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TABLE E1. Additional laboratory parameters of 2 patients with LRBA deficiency
Patient 1 Patient 2
Before HSCT After HSCT Before rituximab After rituximab
Humoral immune system 99.98% donor chimerismk{{*** (IVIG substituted)
Anti–tetanus toxoid antibody Good response ND NA NA
Anti–Haemophilus influenzae B
polysaccharide antibody
Good response ND NA NA
IgG against EBV NA ND Negative{ NA
IgG against EBNA1 NA ND NA NA
IgG against CMV Negative* ND 208 U/mL{ NA
IgG against hepatitis B Negative* ND NA NA
Polio IgG Good response ND NA NA
ANCA Negative/unspecific* Negative/unspecifick Negative Negative
TPO antibody ND Negative{{ Negative Negative
TR antibody ND Negative{{ Negative Negative
TG antibody Positive (negative) Negative{{ Negative Negative
Islet cell antibody Positive (negative) Negative{{ Positive Negative
Insulin antibody ND ND Negative Negative
Glutamate decarboxylase antibody ND Negative§ ND 11.9 U/L (0-9.5 U/L)
Tyrosine phosphatase antibody ND ND ND Negative
21-Hydroxylase antibody ND ND ND Normal
Gliadin IgA antibody 150 (<25) ND ND Negative
Gliadin IgG antibody 25 (<25) ND ND Negative
Transglutaminase antibody ND ND ND Negative
Endomysial IgG antibody Negative ND ND. Negative
Laboratory chemistry (selected parameters)
TSH Normal Normal Normal 6.56 mU/mL (0.1-4 mU/mL)
fT4 Normal Normal Normal 15.1 pmol/L (9.5-24 pmol/L)
Elastase/stool (mg E1/g) 22-88* (200-2500) ND ND 141-156§§ (200-2500)
Calprotectin/stool (mg/g) ND ND 272* (0-100) 1331 (0-100)
Vitamin B12 (pg/mL) ND ND 285** (180-1100) 179 (180-1100)
Vitamin A ND ND ND 23 mg/dL§§ (30-70 mg/dL)
Vitamin D3 ND ND ND 5.6 ng/mL (30-60 ng/mL)
Vitamin E ND ND ND 7 mmol/L§§ (12-46 mmol/L)
Prothrombin time Normal Normal Normal 57% (70% to 120%)
Cellular immune system
TREC copies/105 CD31CD451 cells ND 0{{ j 0*** ND 2.13kk
Vb spectratyping (diversity in CD41
and CD81 T cells)
ND CD41 normal; mildly
reduced in CD81***
ND Normal in CD41; mildly
reduced in CD81kk
Phagocyte function (oxidative burst,
phagocytosis; Escherichia coli, DHR)
Normal* ND ND ND
Apoptosis assay (PHA- or IL-2–activated
T cells; annexin V staining)
Normal* (anti-CD95) ND ND Normal§§ (IL-2 withdrawal)
ADA activity Normal* ND ND ND
PNP activity Normal* ND ND ND
Genetic analyses done before performance
of whole-exome sequencing
CD95, CD95L, caspase 8, caspase 10 Normal Normal#
CTLA4 SNPs, SAP, XIAP Normal Normal#
HLA-DQ8 Positive Positive
Footnotes indicate time point of analysis. Pathologic results are shown in boldface (normal ranges are in parentheses).
ADA, Adenosine desaminase; ANCA, anti-neutrophil cytoplasmic antibodies; CMV, cytomegalovirus; DHR, dihydrorhodamine; fT4, free thyroxine; NA, not applicable under IVIG
substitution and not done before IVIG; ND, not done; PNP, purine nucleoside phosphorylase; SAP, signaling lymphocytic activation molecule (SLAM)-associated protein; SNP,
single nucleotide polymorphism; TG, thyreoglobulin; TPO, thyroid peroxidase; TR, thyroid stimulating hormone receptor antibody; TSH, thyroid stimulating hormone; XIAP,
X-linked inhibitor of apoptosis.
*At 6 years of age.
At 8 years.
Low/negative after a break of repetitive IVIG therapy at 6 years; good response/high normal values after one booster vaccination at 6.5 years of age.
§At 10 years.
kAt 14 years (4 years after stem cell transplantation).
{At 17 months.
#At 2 years.
**At 5.5 years before immunosuppression/rituximab.
At 7.5 years of age.
At 9 years of age.
§§At 10 years of age.
kkAt 11 years of age.
{{At 19 years of age (9 years after HSCT).
***At 19.5 years of age (10 years after stem cell transplantation).
See the Methods section in this article’s Online Repository.
At repeated occasions.
J ALLERGY CLIN IMMUNOL
VOLUME 135, NUMBER 5
LETTERS TO THE EDITOR 1390.e7
TABLE E2. List of candidate mutations identified in the index patient
Function Gene Protein name Exonic function Amino acid change dbSNP137
1 Exonic LRBA LPS-responsive vesicle trafficking, beach
and anchor containing
Frameshift deletion NM_001199282:c.7162delA:p.T2388fs
2 Exonic LRBA LPS-responsive vesicle trafficking, beach and anchor containing Nonsynonymous SNV NM_001199282:c.A2444G:p.N815S rs140666848
3 Exonic PAPSS1 39-Phosphoadenosine 59-phosphosulfate synthase 1 Nonsynonymous SNV NM_005443:c.C997T:p.R333C rs35176475
4 Exonic FAT4 FAT atypical cadherin 4 Nonsynonymous SNV NM_024582:c.C6970T:p.R2324W
5 Exonic FAT4 FAT atypical cadherin 4 Nonsynonymous SNV NM_024582:c.G9577A:p.V3193I rs143764643
6 Exonic MAML3 Mastermind-like 3 (Drosophila) Nonframeshift deletion NM_018717:c.2302_2304del:p.768_768del rs5862430
7 Exonic SLC10A7 Solute carrier family 10, member 7 Nonsynonymous SNV NM_001029998:c.T806C:p.V269A
8 Exonic WNK2 WNK lysine deficient protein kinase 2 Nonsynonymous SNV NM_006648:c.A83T:p.E28V
9 Exonic C9orf129 Chromosome 9 open reading frame 129 Nonsynonymous SNV NM_001098808:c.C359T:p.A120V rs4744219
10 Exonic C9orf129 Chromosome 9 open reading frame 129 Nonsynonymous SNV NM_001098808:c.G274A:p.G92S rs3122944
11 Exonic NUTMF NUT family member 2F Nonframeshift deletion NM_017561:c.2071_2073del:p.691_691del rs150455117
12 Exonic NUTMF NUT family member 2F Nonsynonymous SNV NM_017561:c.C410G:p.S137C rs202099818
13 Exonic FOXE1 Forkhead box E1 (thyroid transcription factor 2) Nonframeshift deletion NM_004473:c.511_516del:p.171_172del
14 Exonic COL15A1 Collagen, type XV, alpha 1 Nonsynonymous SNV NM_001855:c.A3002G:p.K1001R rs35544077
15 Splicing ABCA1 ATP-binding cassette, sub-family A (ABC1), member 1 NM_005502:exon41:c.5383-2->TTT
16 Splicing SVEP1 Sushi, von Willebrand factor type A, EGF and pentraxin
domain containing 1
NM_153366:exon47:c.10505-2->T
17 Exonic DNAJC25 DnaJ (Hsp40) homolog, subfamily C, member 25 Nonsynonymous SNV NM_001015882:c.T486G:p.F162L
18 Splicing OLFML2A Olfactomedin-like 2A NM_182487:exon3:c.46211G>T
19 Exonic RABEPK Rab9 effector protein with kelch motifs Nonsynonymous SNV NM_005833:c.C217T:p.H73Y rs1128362
20 Exonic FAM73B Family with sequence similarity 73, member B Nonsynonymous SNV NM_032809:c.T299C:p.V100A rs11544968
21 Exonic USP20 Ubiquitin specific peptidase 20 Nonframeshift deletion NM_001008563:c.1072_1074del:p.358_358del rs10602985
22 Exonic PPAPDC3 Phosphatidic acid phosphatase type 2 domain containing 3 Nonsynonymous SNV NM_032728:c.G26A:p.R9H rs148406586
23 Exonic GTF3C4 General transcription factor IIIC, polypeptide 4, 90kDa Nonsynonymous SNV NM_012204:c.G10A:p.A4T rs143172300
24 Exonic GOLGA6L10 Golgin A6 family-like 10 Nonsynonymous SNV NM_001164465:c.G1025A:p.R342Q rs201670904
25 Exonic GOLGA6L10 Golgin A6 family-like 10 Nonsynonymous SNV NM_001164465:c.G1007A:p.R336Q rs200685620
26 Exonic ALKBH3 alkB, alkylation repair homolog 3 Nonsynonymous SNV NM_139178:c.C684G:p.D228E rs1130290
27 Splicing CREB3L1 cAMP responsive element binding protein 3-like 1 NM_052854:exon12:c.1524-1->G rs79068197
28 Exonic ACP2 Acid phosphatase 2, lysosomal Nonsynonymous SNV NM_001610:c.T1177C:p.F393L rs145420520
29 Exonic ALPK3 Alpha-kinase 3 Nonsynonymous SNV NM_020778:c.G4289A:p.R1430Q rs150023454
30 Exonic ACAN Aggrecan Nonsynonymous SNV NM_001135:c.G1274A:p.G425E
SNV, Single nucleotide variant. JA
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